Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.